Form D · Biotechnology
Renova Therapeutics, Inc.
Carlsbad, CA · CIK 0002036392
Offering snapshot reported Sep 9, 2024 · SEC filing
- Reported sold
- $167K Offering amount: $500K
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 23, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 9, 2024 | Initial | $166,500 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-523564
Source: Form D, filed Sep 9, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Roy Cosan | Director |
| William Davidson | Director |
| Kirk Hammond | Director |
| Pierre Lecocq | Director |
| Vijay Mahant | Director |
| Shawn Swaney | Executive |
| Michael Torres | Director |
| Morgan Xu | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
701 Palomar Airport Road Suite 300
Carlsbad, CA, 92011
Carlsbad, CA, 92011